Thousand Oaks-based biotech giant Amgen won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market, Bloomberg News reported Aug. 27.

The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement from the agency.